Healthcare Industry News: drug-eluting balloon
News Release - November 4, 2011
Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure
MINNEAPOLIS--(Healthcare Sales & Marketing Network)-- Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE:MDT ) today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7–11 in San Francisco. Transcatheter Cardiovascular Therapeutics (TCT) is the world’s largest educational meeting specializing in interventional cardiovascular medicine.
TCT 2011 includes a host of clinical updates on a range of Medtronic devices, some of which are investigational in the United States:*
- Resolute® and Endeavor® Zotarolimus-Eluting Coronary Stents*
- Assurant® Cobalt Iliac Balloon-Expandable Stent and Complete SE® (Self-Expanding) Vascular Stent
- IN.PACT™ drug-eluting balloons*
- CoreValve® System Transcatheter Aortic Valve*
- Endurant® AAA Stent Graft
- Symplicity® Renal Denervation System*
Oral presentations related to Medtronic products are listed chronologically below in U.S. Pacific Standard Time. These include presentations related to the company’s peripheral stents on Monday; drug-eluting coronary stents, aortic stent grafts and renal denervation system on Tuesday; and drug-eluting balloons on Thursday. The CoreValve System is the subject of multiple presentations Monday through Thursday. In addition, the late-breaking clinical trials session on Friday includes TWENTE, a head-to-head comparison of Medtronic’s Resolute and Abbott Laboratories’ Xience V drug-eluting stents.
Monday, Nov. 7
11:20am–2:20pm / Endovascular Interventions (Part 1) / Session III. Emerging Approaches in Vascular Intervention (Room 131)
- 11:30am / Twelve-Month Results from the COMPLETE SE Study of SFA Stenting
- 11:55am / Outcomes of Iliac Intervention Using a Co-Cr Balloon Expandable Stent: Final Results of the ACTIVE Study
- 1:30pm / Deeper in the Pelvis: Status of Pudendal Artery Stenting for Erectile Dysfunction
- 2:05pm / The Australia-New Zealand Multicenter TAVR Registry Experience
- 3:38pm / Updates from the US CoreValve Pivotal Randomized Trial
- 4:01pm / Self-Expanding CoreValve TAVR: Valve-in-Valve, Bicuspid Disease, an Aortic Regurgitation
- 4:21pm / SURTAVI
- 5:47pm / Drug-Eluting Stents for the Treatment of Erectile Dysfunction: Results of the ZEN Trial
- 6:15pm / CoreValve Subclavian: A Single-Center, Propensity-Case-Controlled Registry of Transcatheter Aortic Valve Implantation via Subclavian vs. Transfemoral Access
10:15am–12:30pm / Drug-Eluting Stents II (Room 111)
- 10:15am / Final 5 Year Follow-up from the RESOLUTE First in Man Trial
- 10:28am / One-Year Outcomes in Over 1,500 Patients with Diabetes Treated with the Resolute Zotarolimus-Eluting Stent
- 10:41am / Short and Long-term Safety and Effectiveness of Transcatheter Aortic Valve Implantation in a Failing Surgical Aortic Bioprosthesis
- 10:28am / TAVR for High-risk Patients with Severe Aortic Stenosis Who Satisfy All the Criteria for Conventional Aortic Valve Replacement: A United Kingdom-Based Cost-Utility Analysis Discussion
- 11:46am / Twelve-month Results from the CoreValve Transcatheter Aortic Valve Australia-New Zealand Study
- 10:54am / The “Final” Five-Year Follow-up from the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent with A Paclitaxel-Eluting Stent
- 11:07am / Pooled Analysis of RESOLUTE Clinical Trial Long-term Safety Data
- 11:46am / From US Pivotal Study to 1,200 Patients on 6 Continents: A Global Perspective on the Endurant Stent Graft
- 2:33pm / Renal Nerve Ablation (Ardian): Potential for Heart Failure
- 4:15pm / Latest Results from Renal Denervation Therapy in Refractory HTN: The Symplicity HTN-1 and Symplicity HTN-2 Trials
- 4:30pm / Lessons Learned and Trial Design for the U.S. Pivotal Symplicity HTN-3 Trial
2:00–3:30pm / Surgical, Interventional & Hybrid Procedures (Room 133)
- 2:16pm / If Transfemoral is Not Available, Alternative Vascular Access is Preferable to Transapical
- 3:00pm / TAVR: Parade of Next Generation Devices
8:00–11:00am / Morning Spotlight Sessions: Next Generation Transcatheter Aortic Valve Therapies / Session I. New and Novel Transcatheter Aortic Valve Systems (Room 135)
- 8:34am / Results from the Engager Transapical TAVR System (formerly Ventor Embracer)
- 3:03pm / Invatec: Technology Overview and Latest Peripheral Data
- 3:13pm / Invatec: Latest Coronary Data
- 3:21pm / Discussion with Audience Q&A: Critical Appraisal of the Invatec Technology and Results
11:00am–1:10pm / Plenary Session XXI. Late Breaking Clinical Trials and First Report Investigations III / Focus on Optimal PCI (Esplanade Ballroom)
- 11:55am / TWENTE: A Prospective, Randomized Trial of Zotarolimus-Eluting Stents and Everolimus-Eluting Stents in Patients with Coronary Artery Disease
The Resolute DES, IN.PACT DEB, CoreValve System and Symplicity System are all investigational devices in the United States, where their use is limited by U.S. law to clinical studies approved by the FDA. The Endeavor DES, Complete SE and Assurant Cobalt stents, and Endurant stent graft have all obtained FDA approval and are commercially available for clinical use in the United States.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMedtronic TYRX(TM) Absorbable Antibacterial Envelope Is Cost Effective for Patients at Increased Risk of Infections
Medtronic Study Finds Opioid-Induced Respiratory Depression in the Hospital More Common and Costly
Jeffrey J. Popma, M.D. to Join Medtronic as Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart Businesses